交银国际近期发布研报称，首次覆盖劲方医药，给予买入评级，目标价51港元。交银国际表示，作为一 家扎根中国内地、拥有全球视野的创新药企，劲方医药组建了一支平均拥有逾20年行业经验、执行力较 强的核心管理团队，建立了一条包括6款临床阶段候选药物的药物管线。 2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中劲方医药- B(02595)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一) 起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，劲方医药有可能被调入港股 通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...

Group 1: Core Insights - The China Securities Regulatory Commission has confirmed the overseas listing applications for Puhui Medical and Baoji Pharmaceutical, both aiming for a listing in Hong Kong [1] Group 2: Puhui Medical - Puhui Medical plans to issue no more than 34,500,000 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [2] - The company submitted its prospectus to the Hong Kong Stock Exchange on April 30, but the prospectus has since expired. Puhui Medical specializes in the research, production, and sales of medical X-ray imaging equipment and orthopedic surgical robots, covering over 100 products across nine major series [4] - Financially, Puhui Medical reported revenues of 377 million yuan, 501 million yuan, and 484 million yuan for the fiscal years 2022 to 2024, with corresponding net losses of 43.7 million yuan, 15.97 million yuan, and 44.23 million yuan [5] Group 3: Baoji Pharmaceutical - Baoji Pharmaceutical plans to issue no more than 110,426,740 overseas listed ordinary shares and list on the Hong Kong Stock Exchange [6] - The company submitted its prospectus to the Hong Kong Stock Exchange on August 21, having previously submitted an application on January 21, 2025. Baoji Pharmaceutical is a clinical-stage biotechnology company focused on addressing complex diseases with limited treatment options. As of August 2025, it has seven clinical-stage candidates, including three core products, and holds nine authorized patents along with ten patent applications [8] - In terms of financial performance, Baoji Pharmaceutical reported revenues of 6.93 million yuan, 6.16 million yuan, and 4.20 million yuan for 2023, 2024, and the first six months of 2025, with corresponding net losses of 160 million yuan, 364 million yuan, and 183 million yuan [8]